



14 April 2023

ASX Code: MXC

LSE Code: MXC

Issue of Shares – Cleansing Notice

MGC Pharmaceuticals Ltd ('MGC Pharma' or the 'Company') advises that today, 180,005,680 Fully Paid Ordinary Shares were issued and allotted to sophisticated investors as part of the first tranche of shares pursuant to the capital raising announced on 11 April 2023 and 13 April 2023.

Pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Corporations Act**), the Company gives notice in relation to the Shares issued above, that:

- (a) the Company issued the Shares without disclosure under Part 6D.2 of the Corporations Act;
- (b) at the date of this Notice, the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company;
- (c) at the date of this Notice, the Company has complied with section 674 and 674A of the Corporations Act as it applies to the Company; and
- (d) at the date of this Notice, there is no information to be disclosed which is "excluded information" as defined in subsection 708A(7) of the Corporations Act that is reasonable for investors and their professional advisors to find in a disclosure document.

—Ends—

Authorised for release by the board of directors, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer
CEO & Managing Director
+61 8 6382 3390
info@mgcpharma.co.uk

UK PR Advisors

Tavistock
Charles Vivian / Tim Pearson
+44 207 920 3150
mgcpharma@tavistock.co.uk

UK Financial Consultant

SW4 Partners
Rupert Fane / Nilesh Patel
rupert@sw4partners.com / nilesh@sw4partners.com

MGC Pharmaceuticals Ltd

Arron Canicais / Rowan Harland
Joint Company Secretaries
+61 8 6382 3390
info@mgcpharma.co.uk

UK Brokers

Peterhouse Capital
Charles Goodfellow / Lucy Williams
+44 207 469 0930
cg@peterhousecap.com / lw@peterhousecap.com

A
S
X

R
E
L
E
A
S
E

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil, and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma